Alzheimer ’s Drug Solanezumab Fails in Phase 3 Clinical Trial

This study was the first major Alzheimer ’s clinical trial to require molecular evidence of amyloid deposition in the brain for enrollment. While the treatment did have some favorable effects, in the main measure of outcome — measured with a cognitive test called the Alzheimer’s Disease Assessment Scale-cognitive subscale —the researchers did not observe any statistically significant benefit compared with placebo.One Good Reason To Consider an Alzheimer's Clinical TrialThe authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough drug was administered or that the drug needs to be administered earlier in the disease course.In other studies ongoing at Columbia University Irving Medical Center and other centers, solanezumab is being evaluated in presymptomatic patients at risk of Alzheimer ’s disease. Other Alzheimer ’s drugs are also in development and being tested at higher doses.Search our Award Winning Alzheimer's Reading Room Knowledge Base for Answers to Your Questions, and Solutions to Problems“Although we are disappointed that this particular drug did not prove successful, the field is benefiting from each study,” says lead author Lawrence Honig, MD, PhD, professor of neurology at CUIMC. “There is hope that one of the newer ongoing studies may result in an effective treatment for s lowing the course of Alzheimer’s disease.”W...
Source: Alzheimer's Reading Room, The - Category: Neurology Tags: alzheimers clinical tiral alzheimers symptoms clinical trial news solanezumab Source Type: blogs

Related Links:

CONCLUSIONS: Brexpiprazole 2 mg/day has the potential to be efficacious, safe, and well tolerated in the treatment of AAD. PMID: 31708380 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
(Alzheimer's Association) 5-year grant aimed at identifying evidence-based strategies to enhance care and support for individuals with dementia and their care partners.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Alzheimer’s disease (AD) is a neurodegenerative disease and the main cause of dementia. Its major symptom is memory loss, which is a result of neuronal cell death, which is accompanied by neuroinflammation. Some studies indicate the overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway in this disease, being, thus, a potential target for pharmacological treatment. Here, we used a transgenic mouse model of AD that expresses a mutant amyloid-β precursor protein (T41 mice) to investigate the effects of dactolisib (alternative name: NVP-BEZ23...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Keeping blood pressure in check may lower the risk of Alzheimer ’s disease and other forms of dementia.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Alzheimer ' s Disease Blood Pressure Dementia Source Type: news
Funding Opportunity RFA-AA-20-006 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimers disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimers disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Authors: Nikolac Perkovic M, Pivac N Abstract Alzheimer's disease is a complex and heterogeneous, severe neurodegenerative disorder and the predominant form of dementia, characterized by cognitive disturbances, behavioral and psychotic symptoms, progressive cognitive decline, disorientation, behavioral changes, and death. Genetic background of Alzheimer's disease differs between early-onset familial Alzheimer's disease, other cases of early-onset Alzheimer's disease, and late-onset Alzheimer's disease. Rare cases of early-onset familial Alzheimer's diseases are caused by high-penetrant mutations in genes coding for...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
(Technical University of Denmark) Scientists prove that ergothioneine, an important compound that may be used to delay the onset of diseases such as Alzheimer's and dementia, can be produced in baker's yeast.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Authors: Kim YG, Park DG, Moon SY, Jeon JY, Kim HJ, Kim DJ, Lee KW, Han SJ Abstract BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with an increased risk for dementia. The effects of hypoglycemia on dementia are controversial. Thus, we evaluated whether hypoglycemia increases the risk for dementia in senior patients with T2DM. METHODS: We used the Korean National Health Insurance Service Senior cohort, which includes>10% of the entire senior population of South Korea. In total, 5,966 patients who had ever experienced at least one episode of hypoglycemia were matched with those who had not, using p...
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
We reported dichotomous outcomes as risk ratio (RR) with 95% CI. We assessed the strength of the available evidence using the GRADE approach. MAIN RESULTS: We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow-up ranged from 15 days to three years. Five of...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
ive Abstract Ventricular enlargement occurs in several neurodegenerative and psychiatric diseases. A large genome-wide association study (GWAS) has identified seven loci associated with ventricular volume. The rate of ventricular enlargement increased in the progression of disease from normal cognition to dementia. Here, we aimed to use the rate of ventricular enlargement as an endophenotype for the development and progression of neurodegenerative diseases to discover more common genetic variants. We performed a GWAS of the rate of ventricular enlargement using 507 nondemented non-Hispanic white participants from ...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Dementia | Legislation | Neurology | Pfizer | Statistics | Study